Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.
Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.
复制标题
DOI：
10.3390/ijms24054476
复制
发表时间：
2023-02-24
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
姜黄（Curcuma longa L.）几个世纪以来一直被用作抗炎的植物，归因于其多酚类姜黄素，其中姜黄素占主导地位。虽然“姜黄素”补充剂是最畅销的植物药，具有良好的临床前效果，但关于人体生物活性的问题仍然存在。为了解决这个问题，进行了范围审查，以评估报告口服姜黄素对疾病结局影响的人类临床试验。使用既定的指南检索了8个数据库，得到389篇符合纳入标准的引文（来自9528篇初始引文）。一半集中在肥胖相关的代谢紊乱（29%）或肌肉骨骼疾病（17%），其中炎症是一个关键的驱动因素，在主要是双盲，随机和安慰剂对照试验（77%，D-RCT）的研究中，大多数引文（75%）报告了对临床结局和/或生物标志物的有益作用。其次研究最多的疾病类别（神经认知[11%]或胃肠道疾病[10%]或癌症[9%]）的引文数量要少得多，并根据研究质量和研究条件产生混合结果。虽然需要额外的研究，包括在较大的D-RCT研究中对不同姜黄素制剂和剂量进行系统评价，但目前对几种高度研究的疾病（例如，代谢综合征、骨关节炎）也是临床上常见的，提示了临床益处。
Medicinal properties of turmeric (Curcuma longa L.), a plant used for centuries as an anti-inflammatory, are attributed to its polyphenolic curcuminoids, where curcumin predominates. Although “curcumin” supplements are a top-selling botanical with promising pre-clinical effects, questions remain regarding biological activity in humans. To address this, a scoping review was conducted to assess human clinical trials reporting oral curcumin effects on disease outcomes. Eight databases were searched using established guidelines, yielding 389 citations (from 9528 initial) that met inclusion criteria. Half focused on obesity-associated metabolic disorders (29%) or musculoskeletal disorders (17%), where inflammation is a key driver, and beneficial effects on clinical outcomes and/or biomarkers were reported for most citations (75%) in studies that were primarily double-blind, randomized, and placebo-controlled trials (77%, D-RCT). Citations for the next most studied disease categories (neurocognitive [11%] or gastrointestinal disorders [10%], or cancer [9%]), were far fewer in number and yielded mixed results depending on study quality and condition studied. Although additional research is needed, including systematic evaluation of diverse curcumin formulations and doses in larger D-RCT studies, the preponderance of current evidence for several highly studied diseases (e.g., metabolic syndrome, osteoarthritis), which are also clinically common, are suggestive of clinical benefits.
登录
查看更多内容
影响因子：
4.5
作者：
Akazawa, Nobuhiko;Choi, Youngju;Maeda, Seiji
通讯作者：
Maeda, Seiji
影响因子：
3.6
作者：
Amin, F.;Istam, N.;Gilani, A. H.
通讯作者：
Gilani, A. H.
影响因子：
2.4
作者：
Amalraj, Augustine;Varma, Karthik;Gopi, Sreeraj
通讯作者：
Gopi, Sreeraj
DOI：
10.1007/s00464-011-1793-z
发表时间：
2011-12-01
影响因子：
3.1
作者：
Agarwal, Krishna Adit;Tripathi, C. D.;Saluja, Satish
通讯作者：
Saluja, Satish
影响因子：
7.2
作者：
Adibian, Mahsa;Hodaei, Homa;Hedayati, Mehdi
通讯作者：
Hedayati, Mehdi